The GLCCI1/STAT3 pathway: a novel pathway involved in diabetic cognitive dysfunction and the therapeutic effect of...

Area of Science:

• Neuroscience
• Endocrinology
• Molecular Biology

Background:

• Diabetic cognitive dysfunction (DCD) is a serious diabetes complication affecting quality of life.
• Glucocorticoid-induced transcript 1 (GLCCI1) is implicated in inflammation, apoptosis, and autophagy but its role in DCD is unknown.
• Salidroside (SAL) is a potential therapeutic for DCD due to its known neuroprotective effects.

Purpose of the Study:

• To investigate the distribution and role of GLCCI1 in the brain, specifically in DCD.
• To explore the therapeutic potential of salidroside (SAL) in DCD.
• To elucidate the molecular mechanisms underlying DCD and SAL's effects, focusing on the GLCCI1/STAT3 axis.

Main Methods:

• Localization studies of GLCCI1 in hippocampal neurons of C57BL/6J mice.
• Analysis of gene and protein expression (GLCCI1, Bcl-2, p-STAT3/STAT3, Bax, Cleaved Caspase-3/Caspase-3) in DCD models.
• Experimental manipulation including GLCCI1 overexpression and SAL administration.
• Assessment of morphological changes in hippocampal neurons.

Main Results:

• GLCCI1 was found in hippocampal neurons.
• DCD mice showed decreased GLCCI1 and Bcl-2, and increased p-STAT3/STAT3, Bax, and Cleaved Caspase-3/Caspase-3.
• Overexpression of GLCCI1 or SAL administration ameliorated DCD, reversed molecular changes, and improved neuronal morphology.
• SAL exhibited effects similar to GLCCI1 overexpression, including attenuation of GLCCI1 and p-STAT3 expression.

Conclusions:

• The GLCCI1/STAT3 axis plays a critical role in the pathogenesis of diabetic cognitive dysfunction.
• Salidroside (SAL) demonstrates therapeutic potential for DCD by modulating the GLCCI1/STAT3 pathway.
• These findings highlight GLCCI1 as a potential therapeutic target for managing DCD.